Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Inclusion criteria

• Subject has a clinical diagnosis of primary hyperhidrosis of the palms
• Subject is currently drug-naïve for hyperhidrosis medications
• Females must be post-menopausal, surgically sterile, or use an effective method of birth control.

Exclusion criteria

• Subject is pregnant, lactating, is planning to become pregnant during the study, or is less than one year postpartum.
• Subject is a smoker within one year prior to Visit 1/Screening.
• Subject has known history of secondary hyperhidrosis.
• Subject has existence of neurological, psychiatric, endocrine, or other disease that can cause secondary hyperhidrosis or affect sweating.
• Subject has known history of Sjögren's syndrome or Sicca syndrome.
• Subject has used any of the following hyperhidrosis medications or therapies within the specified timeframe:

• Iontophoresis to the palms within four weeks prior to baseline visit;
• Botulinum toxin to the palms within one year prior to baseline visit;
• Prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands);
• Prior medical device treatment to the palms (approved or investigational);
• Any treatments for hyperhidrosis within four weeks prior to baseline visit.
• Subject is currently enrolled in an investigational drug or device study.
• Subject has previously participated in a clinical study of dexmecamylamine or TC-5214.
• Subject has used an investigational drug or investigational device treatment within 30 days prior to baseline.
• Subject has a history of sensitivity to any of the ingredients in the study drugs.